Upregulation of miR-96 Enhances Cellular Proliferation of Prostate Cancer Cells through FOXO1

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Haflidadóttir, Benedikta S ^a   Larne, Olivia ^a   Martin, Myriam ^a   Persson, Margareta ^a   Edsjö, Anders ^a,b   Bjartell, Anders ^a   Ceder, Yvonne ^a  

^a LUND UNIVERSITY   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 96; TRANSCRIPTION FACTOR FKHR; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ADULT; AGED; ARTICLE; BINDING SITE; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CARCINOGENESIS; CELL GROWTH; CELL PROLIFERATION; COHORT ANALYSIS; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; PROGNOSIS; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATE HYPERTROPHY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL TIME; TRANSURETHRAL RESECTION; UPREGULATION;

3' UNTRANSLATED REGIONS; BASE PAIRING; BASE SEQUENCE; CELL LINE, TUMOR; CELL PROLIFERATION; COHORT STUDIES; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICRORNAS; PROSTATIC NEOPLASMS; RNA INTERFERENCE;

EID: 84881538006     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0072400     Document Type: Article

References (37)

1. Ferlay J, Bray F, Forman D, Mathers C, Parkin DM, (2010) GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Available from: http://globocan.iarc.fr. Lyon, France: International Agency for Research on Cancer. Accessed 12 March 2013.
2. Klein EA, Ciezki J, Kupelian PA, Mahadevan A, (2009) Outcomes for intermediate risk prostate cancer: are there advantages for surgery, external radiation, or brachytherapy? Urol Oncol 27: 67-71. doi:10.1016/j.urolonc.2008.04.001. PubMed: 19111801.
3. Gleave ME, Goldenberg SL, Chin JL, Warner J, Saad F, et al. (2001) Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects. J Urol 166: 500-5067. doi:10.1016/S0022-5347(05)65971-X. PubMed: 11458055.
4. Whittington R, Broderick GA, Arger P, Malkowicz SB, Epperson RD, et al. (1999) The effect of androgen deprivation on the early changes in prostate volume following transperineal ultrasound guided interstitial therapy for localized carcinoma of the prostate. Int J Radiat Oncol Biol Phys 44: 1107-1110. doi:10.1016/S0360-3016(99)00119-4. PubMed: 10421544.
5. Navon R, Wang H, Steinfeld I, Tsalenko A, Ben-Dor A, et al. (2009) Novel rank-based statistical methods reveal microRNAs with differential expression in multiple cancer types. PLOS ONE 4: e8003. doi:10.1371/journal.pone.0008003. PubMed: 19946373.
6. Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL, et al. (2007) MicroRNA expression profiling in prostate cancer. Cancer Res 67: 6130-6135. doi:10.1158/0008-5472.CAN-07-0533. PubMed: 17616669.
7. Schaefer A, Jung M, Mollenkopf HJ, Wagner I, Stephan C, et al. (2010) Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer 126: 1166-1176. PubMed: 19676045.
8. Catto JW, Alcaraz A, Bjartell AS, De Vere White R, Evans CP, et al. (2011) MicroRNA in prostate, bladder, and kidney cancer: a systematic review. Eur Urol 59: 671-681. doi:10.1016/j.eururo.2011.01.044. PubMed: 21296484.
9. Sevli S, Uzumcu A, Solak M, Ittmann M, Ozen M, (2010) The function of microRNAs, small but potent molecules, in human prostate cancer. Prostate Cancer Prostatic Dis 13: 208-217. doi:10.1038/pcan.2010.21. PubMed: 20585343.
10. Fang YX, Gao WQ, (2013) Roles of microRNAs during prostatic tumorigenesis and tumor progression. Oncogene: ([MedlinePgn:]) doi:10.1038/onc.2013.54. PubMed: 23455326. PubMed: 23455326.
11. Larne O, Martens-Uzunova E, Hagman Z, Edsjö A, Lippolis G, et al. (2012) miQ-A novel microRNA based diagnostic and prognostic tool for prostate cancer. Int J Cancer 132: 2867-2875. PubMed: 23184647.
12. Bandrés E, Cubedo E, Agirre X, Malumbres R, Zárate R, et al. (2006) Identification by Real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues. Mol Cancer 5: 29. doi:10.1186/1476-4598-5-29. PubMed: 16854228.
13. Wang Y, Huang JW, Calses P, Kemp CJ, Taniguchi T, (2012) MiR-96 downregulates REV1 and RAD51 to promote cellular sensitivity to cisplatin and PARP inhibition. Cancer Res 72: 4037-4046. doi:10.1158/0008-5472.CAN-12-0103. PubMed: 22761336.
14. Yu S, Lu Z, Liu C, Meng Y, Ma Y, et al. (2010) miRNA-96 suppresses KRAS and functions as a tumor suppressor gene in pancreatic cancer. Cancer Res 70: 6015-6025. doi:10.1158/0008-5472.CAN-09-4531. PubMed: 20610624.
15. Lin H, Dai T, Xiong H, Zhao X, Chen X, et al. (2010) Unregulated miR-96 induces cell proliferation in human breast cancer by downregulating transcriptional factor FOXO3a. PLOS ONE 5: e15797. doi:10.1371/journal.pone.0015797. PubMed: 21203424.
16. Myatt SS, Wang J, Monteiro LJ, Christian M, Ho KK, et al. (2010) Definition of microRNAs that repress expression of the tumor suppressor gene FOXO1 in endometrial cancer. Cancer Res 70: 367-377. doi:10.1158/1538-7445.AM10-367. PubMed: 20028871.
17. Guttilla IK, White BA, (2009) Coordinate regulation of FOXO1 by miR-27a, miR-96, and miR-182 in breast cancer cells. J Biol Chem 284: 23204-23216. doi:10.1074/jbc.M109.031427. PubMed: 19574223.
18. Jalvy-Delvaille S, Maurel M, Majo V, Pierre N, Chabas S, et al. (2012) Molecular basis of differential target regulation by miR-96 and miR-182: the Glypican-3 as a model. Nucleic Acids Res 40: 1356-1365. doi:10.1093/nar/gkr843. PubMed: 22009679.
19. Xie L, Ushmorov A, Leithäuser F, Guan H, Steidl C, et al. (2012) FOXO1 is a tumor suppressor in classical Hodgkin lymphoma. Blood 119: 3503-3511. doi:10.1182/blood-2011-09-381905. PubMed: 22343918.
20. Huang H, Regan KM, Lou Z, Chen J, Tindall DJ, (2006) CDK2-dependent phosphorylation of FOXO1 as an apoptotic response to DNA damage. Science 314: 294-297. doi:10.1126/science.1130512. PubMed: 17038621.
21. Nakamura N, Ramaswamy S, Vazquez F, Signoretti S, Loda M, et al. (2000) Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN. Mol Cell Biol 20: 8969-8982. doi:10.1128/MCB.20.23.8969-8982.2000. PubMed: 11073996.
22. Schmidt M, Fernandez de Mattos S, van der Horst A, Klompmaker R, Kops GJ, et al. (2002) Cell cycle inhibition by FoxO forkhead transcription factors involves downregulation of cyclin D. Mol Cell Biol 22: 7842-7852. doi:10.1128/MCB.22.22.7842-7852.2002. PubMed: 12391153.
23. Modur V, Nagarajan R, Evers BM, Milbrandt J, (2002) FOXO proteins regulate tumor necrosis factor-related apoptosis inducing ligand expression. Implications for PTEN mutation in prostate cancer. J Biol Chem 277: 47928-47937. doi:10.1074/jbc.M207509200. PubMed: 12351634.
24. Dong XY, Chen C, Sun X, Guo P, Vessella RL, et al. (2006) FOXO1A is a candidate for the 13q14 tumor suppressor gene inhibiting androgen receptor signaling in prostate cancer. Cancer Res 66: 6998-7006. doi:10.1158/0008-5472.CAN-06-0411. PubMed: 16849544.
25. Zhang H, Pan Y, Zheng L, Choe C, Lindgren B, et al. (2011) FOXO1 inhibits Runx2 transcriptional activity and prostate cancer cell migration and invasion. Cancer Res 71: 3257-3267. doi:10.1158/0008-5472.CAN-10-2603. PubMed: 21505104.
26. Yoshimoto M, Cutz JC, Nuin PA, Joshua AM, Bayani J, et al. (2006) Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias. Cancer Genet Cytogenet 169: 128-137. doi:10.1016/j.cancergencyto.2006.04.003. PubMed: 16938570.
27. Whang YE, Wu X, Suzuki H, Reiter RE, Tran C, et al. (1998) Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci U S A 95: 5246-5250. doi:10.1073/pnas.95.9.5246. PubMed: 9560261.
28. Ramaswamy S, Nakamura N, Sansal I, Bergeron L, Sellers WR, (2002) A novel mechanism of gene regulation and tumor suppression by the transcription factor FKHR. Cancer Cell 2: 81-91. doi:10.1016/S1535-6108(02)00086-7. PubMed: 12150827.
29. Liu P, Li S, Gan L, Kao TP, Huang H, (2008) A transcription-independent function of FOXO1 in inhibition of androgen-independent activation of the androgen receptor in prostate cancer cells. Cancer Res 68: 10290-10299. doi:10.1158/0008-5472.CAN-08-2038. PubMed: 19074897.
30. Li P, Lee H, Guo S, Unterman TG, Jenster G, et al. (2003) AKT-independent protection of prostate cancer cells from apoptosis mediated through complex formation between the androgen receptor and FKHR. Mol Cell Biol 23: 104-118. doi:10.1128/MCB.23.1.104-118.2003. PubMed: 12482965.
31. Hagman Z, Larne O, Edsjö A, Bjartell A, Ehrnström RA, et al. (2010) miR-34c is downregulated in prostate cancer and exerts tumor suppressive functions. Int J Cancer 127: 2768-2776. doi:10.1002/ijc.25269. PubMed: 21351256.
32. Hagman Z, Haflidadóttir BS, Ceder JA, Larne O, Bjartell A, et al. (2013) miR-205 negatively regulates the androgen receptor and is associated with adverse outcome of prostate cancer patients. Br J Cancer 108: 1668-1676. doi:10.1038/bjc.2013.131. PubMed: 23571738.
33. Lundwall A, Bjartell A, Olsson AY, Malm J, (2002) Semenogelin I and II, the predominant human seminal plasma proteins, are also expressed in non-genital tissues. Mol Hum Reprod 8: 805-810. doi:10.1093/molehr/8.9.805. PubMed: 12200457.
34. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, et al. (2010) Integrative genomic profiling of human prostate cancer. Cancer Cell 18: 11-22. doi:10.1016/j.ccr.2010.05.026. PubMed: 20579941.
35. Zhu W, Liu X, He J, Chen D, Hunag Y, et al. (2011) Overexpression of members of the microRNA-183 family is a risk factor for lung cancer: a case control study. BMC Cancer 11: 393. doi:10.1186/1471-2407-11-393. PubMed: 21920043.
36. Bohrer LR, Liu P, Zhong J, Pan Y, Angstman J, et al. (2013) FOXO1 binds to the TAU5 motif and inhibits constitutively active androgen receptor splice variants. Prostate 73: 1017-1027. doi:10.1002/pros.22649. PubMed: 23389878.
37. Ma Q, Fu W, Li P, Nicosia SV, Jenster G, et al. (2009) FoxO1 mediates PTEN suppression of androgen receptor N- and C-terminal interactions and coactivator recruitment. Mol Endocrinol 23: 213-225. PubMed: 19074551.